218 related articles for article (PubMed ID: 35207438)
1. Biomarker Potential of Vimentin in Oral Cancers.
Mogre S; Makani V; Pradhan S; Devre P; More S; Vaidya M; Dmello C
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207438
[TBL] [Abstract][Full Text] [Related]
2. Role of Vimentin and E-cadherin Expression in Premalignant and Malignant Lesions of Oral Cavity.
Gupta SK; Agarwal S; Singh SN; Sehra R; Jat PS; Singhal P
Indian J Otolaryngol Head Neck Surg; 2022 Sep; 74(3):350-355. PubMed ID: 36213468
[TBL] [Abstract][Full Text] [Related]
3. Transition of Immunohistochemical Expression of E-Cadherin and Vimentin from Premalignant to Malignant Lesions of Oral Cavity and Oropharynx.
Akhtar K; Ara A; Siddiqui SA; Sherwani RK
Oman Med J; 2016 May; 31(3):165-9. PubMed ID: 27162585
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of vimentin predisposes oral premalignant lesion derived cells towards transformation.
Dmello C; Sawant S; Chaudhari PR; Dongre H; Ahire C; D'Souza ZC; Charles SE; Rane P; Costea DE; Chaukar D; Kane S; Vaidya M
Exp Mol Pathol; 2018 Dec; 105(3):243-251. PubMed ID: 30189187
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of aberrant vimentin expression in oral premalignant lesions and carcinomas.
Sawant SS; Vaidya Mm; Chaukar DA; Alam H; Dmello C; Gangadaran P; Kannan S; Kane S; Dange PP; Dey N; Ranganathan K; D'Cruz AK
Oral Dis; 2014 Jul; 20(5):453-65. PubMed ID: 23865921
[TBL] [Abstract][Full Text] [Related]
6. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis.
Kanojia D; Vaidya MM
Oral Oncol; 2006 Aug; 42(7):655-67. PubMed ID: 16448841
[TBL] [Abstract][Full Text] [Related]
7. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy.
Hugwil AV
Med Hypotheses; 2013 Sep; 81(3):489-95. PubMed ID: 23856243
[TBL] [Abstract][Full Text] [Related]
8. Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory.
Dionne KR; Warnakulasuriya S; Zain RB; Cheong SC
Int J Cancer; 2015 Feb; 136(3):503-15. PubMed ID: 24482244
[TBL] [Abstract][Full Text] [Related]
9. Association between Smokeless Tobacco and risk of malignant and premalignant conditions of oral cavity: A systematic review of Indian literature.
Acharya S; Singh S; Bhatia SK
J Oral Maxillofac Pathol; 2021; 25(2):371. PubMed ID: 34703140
[TBL] [Abstract][Full Text] [Related]
10. Role of Toluidine Blue Staining in Suspicious Lesions of Oral Cavity and Oropharynx.
Vijayakumar V; Reghunathan D; Edacheriyan B; Mukundan A
Indian J Otolaryngol Head Neck Surg; 2019 Oct; 71(Suppl 1):142-146. PubMed ID: 31741949
[TBL] [Abstract][Full Text] [Related]
11. Early genetic changes during upper aerodigestive tract tumorigenesis.
Hittelman WN; Voravud N; Shin DM; Lee JS; Ro JY; Hong WK
J Cell Biochem Suppl; 1993; 17F():233-6. PubMed ID: 8412199
[TBL] [Abstract][Full Text] [Related]
12. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma.
Cruz IB; Snijders PJ; Meijer CJ; Braakhuis BJ; Snow GB; Walboomers JM; van der Waal I
J Pathol; 1998 Apr; 184(4):360-8. PubMed ID: 9664901
[TBL] [Abstract][Full Text] [Related]
13. Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation.
Chaw SY; Abdul Majeed A; Dalley AJ; Chan A; Stein S; Farah CS
Oral Oncol; 2012 Oct; 48(10):997-1006. PubMed ID: 22704062
[TBL] [Abstract][Full Text] [Related]
14. Molecular Insights into Oral Malignancy.
Deshmukh A; Rao KN; Arora RD; Nagarkar NM; Singh A; Shetty OS
Indian J Surg Oncol; 2022 Jun; 13(2):267-280. PubMed ID: 35782825
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics.
Reibel J
Crit Rev Oral Biol Med; 2003; 14(1):47-62. PubMed ID: 12764019
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).
Webber MM; Bello-DeOcampo D; Quader S; Deocampo ND; Metcalfe WS; Sharp RM
Clin Exp Metastasis; 1999 May; 17(3):255-63. PubMed ID: 10432011
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.
Schaaij-Visser TB; Bremmer JF; Braakhuis BJ; Heck AJ; Slijper M; van der Waal I; Brakenhoff RH
Oral Oncol; 2010 Feb; 46(2):123-7. PubMed ID: 20036603
[TBL] [Abstract][Full Text] [Related]
18. Potentially malignant disorders of the oral cavity: a clinical study.
Shukla A
Indian J Otolaryngol Head Neck Surg; 2014 Jan; 66(1):79-85. PubMed ID: 24605307
[TBL] [Abstract][Full Text] [Related]
19. Affinity proteomics led identification of vimentin as a potential biomarker in colon cancers: insights from serological screening and computational modelling.
Bukhari S; Mokhdomi TA; Chikan NA; Amin A; Qazi H; Wani SH; Wafai AH; Tyub S; Mustafa F; Mir MS; Chowdri NA; Qadri RA
Mol Biosyst; 2015 Jan; 11(1):159-69. PubMed ID: 25319351
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of p53, p16 and hTERT in oral squamous cell carcinoma and potentially malignant disorders.
Abrahao AC; Bonelli BV; Nunes FD; Dias EP; Cabral MG
Braz Oral Res; 2011; 25(1):34-41. PubMed ID: 21359449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
